作者
Alexandros Rampotas,Luke Carter‐Brzezinski,Tim C. P. Somervaille,James Forryan,Fotios Panitsas,Claire Harrison,Ruth Witherall,Andrew J. Innes,Louise Wallis,Naumann M. Butt,Bethan Psaila,Adam J. Mead,Matthew Carter,Anna L. Godfrey,Heather Laing,Mamta Garg,Sebastian Francis,Joanne Ewing,Chun Huat Teh,Hannah Bibi Cowen,Peter Dyer,Conall McConville,Frances Wadelin,Ali Sahra,Andrew McGregor,Elizabeth Kulakov,Donal P. McLornan,Jonathan Lambert
摘要
Abstract Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant skin assessment, counseling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
PDF的下载单位、IP信息已删除
浮游
Dean
leaolf
风清扬
iNk
xiaoyinni
馆长
赫若魔
eric888
LaTeXer
无极微光
遇上就这样吧
tuanheqi
pcr163
qc
独孤幻月96
curtisness
pluto
yhhhhh
小葱头
一只小小人
老阎
Criminology34
小杭76
ephore
典雅碧空
yznfly
柴桑青木
皖公网安备34019202002308
